More tools:Markets·Screener·Research Chat

Eli Lilly & Co. (LLY) Financial Statements

Eli Lilly & Co.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S5STL8
XNYS · usd
1,152.54▼ 29.33 (-2.48%)
As of 2026-07-14
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA—
Financial Highlights
Revenue (TTM)$72.2B
Net Income (TTM)$25.3B
EBITDA—
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close1,181.87
Day's Range1,140.74 – 1,166.01
52-Week Range623.78 – 1,249.45
Volume2.63M
Avg Volume3.09M
Share Statistics
Shares Outstanding941.7M
Employees50.0K
ExchangeXNYS
Listed1970-07-09

Key questions about Eli Lilly & Co. (LLY)

What is Eli Lilly & Co.'s Market Cap?
Eli Lilly & Co.'s Market Cap is $1.1T, based on as-reported figures from SEC (XBRL) filings.
What is Eli Lilly & Co.'s Enterprise Value?
Eli Lilly & Co.'s Enterprise Value is $1.1T, based on as-reported figures from SEC (XBRL) filings.
What is Eli Lilly & Co.'s Trailing P/E?
Eli Lilly & Co.'s Trailing P/E is 42.9×, based on as-reported figures from SEC (XBRL) filings.
What is Eli Lilly & Co.'s Price / Sales?
Eli Lilly & Co.'s Price / Sales is 15.0×, based on as-reported figures from SEC (XBRL) filings.
What is Eli Lilly & Co.'s EV / Revenue?
Eli Lilly & Co.'s EV / Revenue is 15.9×, based on as-reported figures from SEC (XBRL) filings.
What is Eli Lilly & Co.'s Revenue (TTM)?
Eli Lilly & Co.'s Revenue (TTM) is $72.2B, based on as-reported figures from SEC (XBRL) filings.
What is Eli Lilly & Co.'s Net Income (TTM)?
Eli Lilly & Co.'s Net Income (TTM) is $25.3B, based on as-reported figures from SEC (XBRL) filings.
What is Eli Lilly & Co.'s Diluted EPS (TTM)?
Eli Lilly & Co.'s Diluted EPS (TTM) is 26.84, based on as-reported figures from SEC (XBRL) filings.
What is Eli Lilly & Co.'s Net Debt?
Eli Lilly & Co.'s Net Debt is $33.6B, based on as-reported figures from SEC (XBRL) filings.
Loading Income Statement…
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
Revenue
YoY growth+55.5%+42.6%+53.9%+37.6%
Costs, expenses, and other:
Cost of sales
Research and development
Marketing, selling, and administrative
Acquired in-process research and development
Asset impairment, restructuring, and other special charges
Other–net, (income) expense
Income before income taxes
Income taxes
Net income
% of revenue37.4%34.4%31.7%36.4%
Earnings per share:
Basic
Diluted
Shares used in calculation of earnings per share:
Basic
Diluted